Qazi Sanjive, Uckun Fatih M
Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA.
J Pers Med. 2023 Apr 29;13(5):770. doi: 10.3390/jpm13050770.
We examined the transcript-level expression of ErbB family protein tyrosine kinases, including ERBB1, in primary malignant lymphoma cells from 498 adult patients with diffuse large B-cell lymphoma (DLBCL). ERBB1 expression in DLBCL cells was significantly higher than in normal B-lineage lymphoid cells. An upregulated expression of ERBB1 mRNA in DLBCL cells was correlated with an amplified expression of mRNAs for transcription factors that recognized ERBB1 gene promoter sites. Notably, amplified ERBB1 expression in DLBCL and its subtypes were associated with significantly worse overall survival (OS). Our results encourage the further evaluation of the prognostic significance of high-level ERBB1 mRNA expression and the clinical potential of ERBB1-targeting therapeutics as personalized medicines in high-risk DLBCL.
我们检测了498例成年弥漫性大B细胞淋巴瘤（DLBCL）患者原发性恶性淋巴瘤细胞中ErbB家族蛋白酪氨酸激酶（包括ERBB1）的转录水平表达。DLBCL细胞中ERBB1的表达显著高于正常B系淋巴细胞。DLBCL细胞中ERBB1 mRNA的上调表达与识别ERBB1基因启动子位点的转录因子mRNA的扩增表达相关。值得注意的是，DLBCL及其亚型中ERBB1表达的扩增与总体生存期（OS）显著较差相关。我们的结果鼓励进一步评估高水平ERBB1 mRNA表达的预后意义以及靶向ERBB1的治疗药物作为高危DLBCL个性化药物的临床潜力。
